Long-Term Effects of Tramadol
Long-term tramadol use is associated with significant risks including dependence, addiction, cognitive impairment, increased depression risk, neurodegeneration, and increased fracture risk, particularly in older adults—these harms often outweigh benefits for chronic pain management.
Key Long-Term Risks
Addiction and Dependence
Tramadol has mu-opioid agonist activity and carries substantial risk for psychological and physical dependence 1. The FDA label explicitly warns that tramadol can be abused and is subject to criminal diversion 1. Physical dependence manifests through withdrawal symptoms including anxiety, sweating, insomnia, rigors, pain, nausea, tremors, diarrhea, and rarely hallucinations when discontinued abruptly 1. Recent evidence shows tramadol has comparable or higher risk of chronic opioid utilization and misuse compared to other opioids 2.
Mental Health Effects
A 2026 retrospective cohort study of 48,066 patients found dose-dependent increased depression risk with longer tramadol use 3. Compared to non-users, adjusted hazard ratios were:
- 1.19 for 1-29 days of use
- 1.26 for 30-89 days
- 1.37 for ≥90 days (p<0.001 for trend) 3
This contradicts earlier assumptions about tramadol's potential antidepressant effects through serotonin-norepinephrine reuptake inhibition.
Neurological Damage
Multiple studies demonstrate tramadol's neurotoxic potential with chronic use:
- Hippocampal atrophy with impaired spatial learning, memory dysfunction, and disrupted long-term potentiation 4
- Cerebellar neurodegeneration causing motor coordination impairment, microgliosis, neuroinflammation, and apoptosis 5
- Seizure risk through nitric oxide inhibition, serotonin reuptake effects, and GABA receptor inhibition 6
- Disruption of GABA metabolism and tricarboxylic acid cycle enzymes in multiple brain regions 7
Fracture Risk
A 2023 cohort study found tramadol increased hip fracture risk in older adults with post-traumatic osteoarthritis (adjusted HR: 1.41), with particularly elevated risk in:
- Males (aHR: 1.83)
- Ages 60-70 years (aHR: 2.11) 8
Cardiovascular and Other Systemic Effects
The 2021 AHA advisory notes tramadol was reclassified as a Schedule IV controlled substance in 2014 due to abuse potential, and recommends reconsidering its use even for short-term musculoskeletal pain 9. Long-term opioid use generally associates with increased cardiovascular events, falls, and all-cause mortality 10.
Guideline Recommendations on Long-Term Use
Limited Role in Chronic Pain
Multiple guidelines position tramadol as second-line or time-limited therapy only:
2023 ASCO Cancer Pain Guideline: Tramadol has "limitations that may make it less desirable than other opioids" including prodrug status, low neurotoxicity threshold limiting dose titration, and multiple drug interactions via CYP450 enzymes 11
2017 HIV/IDSA Chronic Pain Guideline: Tramadol for up to 3 months may help osteoarthritis (weak recommendation, moderate evidence), but opioids should not be first-line for chronic neuropathic pain 12
2010 Mayo Clinic/NeuPSIG Guidelines: Tramadol reserved for patients not responding to first-line medications, with concerns about long-term safety. Risk of abuse "considerably less" than strong opioids but still present 13
2025 NCCN Cancer Pain Guidelines: Maximum 400 mg/day for immediate-release or 300 mg/day for extended-release formulations. Lower doses required for elderly (≥75 years) and those with hepatic/renal dysfunction due to seizure risk. Limited evidence supports tramadol for cancer pain; likely less effective than morphine 14
Specific Limitations
The 2017 ophthalmology guideline notes tramadol's "potential dependence limits it as a second-line agent" and suggests it only when first-line medications fail 15. The 2009 geriatrics guideline warns of seizure risk with high doses or in predisposed patients, plus serotonin syndrome risk when combined with SSRIs 16.
Critical Drug Interactions
Tramadol should be used with extreme caution or avoided with:
- Serotonergic medications (SSRIs, SNRIs, TCAs, MAOIs): Risk of potentially fatal serotonin syndrome 14, 1
- CNS depressants (alcohol, benzodiazepines, other opioids): Additive respiratory depression and overdose risk 1
- CYP450 inhibitors/inducers: Unpredictable metabolism affecting efficacy and toxicity 11
Monitoring Requirements
If tramadol must be used long-term, the 2017 HIV/IDSA guidelines mandate 12:
- Risk assessment before prescribing (strong recommendation)
- Routine monitoring with opioid treatment agreements
- Urine drug testing
- Prescription drug monitoring program checks
- Never use UDT results alone to discharge patients
Safer Alternatives
For chronic pain, guidelines consistently recommend first-line use of:
- Acetaminophen and NSAIDs for musculoskeletal pain 12
- Gabapentinoids, SNRIs, or TCAs for neuropathic pain 15, 13
- Non-pharmacological approaches when feasible
The evidence clearly demonstrates that tramadol's long-term risks—including neurodegeneration, depression, dependence, and fractures—make it inappropriate for routine chronic pain management. When used, it should be time-limited (≤3 months), at lowest effective doses, with close monitoring for adverse effects and signs of misuse.